AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
Last Of Three Phase III Readouts Also Positive
Executive Summary
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.